# Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma

> **NCT05955157** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University of Malaya** · enrollment: 52 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy
- **DRUG:** Tegafur Only Product

## Key facts

- **NCT ID:** NCT05955157
- **Lead sponsor:** University of Malaya
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-03
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955157, "Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05955157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*